Stereotaxis STXS, a global leader in surgical robotics for minimally invasive endovascular intervention, recently announced the successful completion of the first U.S. commercial procedures using its ...
MAGiC is set to receive the CE Mark by early 2025. Tenders will be completed by Q2 or Q3 2025; the FDA approval timeline is similar. The APT acquisition allowed Stereotaxis to complete the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results